Cystic fibrosis
Treatment with mucolytics
Sodium chloride
Sodium chloride 3% inhalation solution 4ml ampoules
To be used as directed.
Sodium chloride 3% inhalation solution 4ml vials
To be used as directed.
Sodium chloride 6% inhalation solution 4ml ampoules
To be used as directed.
Sodium chloride 6% inhalation solution 4ml vials
To be used as directed.
Sodium chloride 7% inhalation solution 4ml vials
To be used as directed.
Dornase alfa
Dornase alfa 2.5mg/2.5ml nebuliser liquid ampoules
2.5mg once daily, administered by jet nebuliser, patients over 21 years may benefit from twice daily dosage.
Prescribing Notes:
- Dornase alfa is used in some patients with cystic fibrosis. It is appropriate for a shared care arrangement to facilitate the seamless transfer of individual patient care from secondary care to general practice.
- Hypertonic saline (7%) may be prescribed in cystic fibrosis.
- Mucolytics are not approved for use in COPD. If prescribed they should be reviewed after 4 weeks to assess if there has been any clinical benefit. If of benefit the dose should be reduced as the condition improves.
History Notes
12/12/2022
Updated sodium chloride inhalation solution options, ERWG Nov 22.
16/02/2022
East Region Formulary content agreed.
Treatment with mucolytics
Sodium chloride
Sodium chloride 3% inhalation solution 4ml ampoules
To be used as directed.
Sodium chloride 3% inhalation solution 4ml vials
To be used as directed.
Sodium chloride 6% inhalation solution 4ml ampoules
To be used as directed.
Sodium chloride 6% inhalation solution 4ml vials
To be used as directed.
Sodium chloride 7% inhalation solution 4ml vials
To be used as directed.
Dornase alfa
Dornase alfa 2.5mg/2.5ml nebuliser liquid ampoules
For dose, refer to BNF for Children.
Prescribing Notes:
- Dornase alfa is used in some patients with cystic fibrosis. It is appropriate for a shared care arrangement to facilitate the seamless transfer of individual patient care from secondary care to general practice.
- Dornase Alfa may also be used in selected patients with non-CF bronchiectasis or similar chronic suppurative lung disease under specialist supervision.
History Notes
30/08/2023
East Region Formulary content agreed - ERFC 09/08/2023.